Nasim Kakavand

Nasim Kakavand

Auto-generated profile, based on publicly available information

Nasim Kakavand

School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2025 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
BDBahar Darouei
Bahar Darouei
RAReza Amani-Beni
Reza Amani-Beni
NKNasim Kakavand
Nasim Kakavand
ASArsham Seifnezhad
Arsham Seifnezhad
SMSadegh Mazaheri-Tehrani
Sadegh Mazaheri-Tehrani
GUGuillermo Umpierrez
Guillermo Umpierrez
Glycemic variability (GV) reflects glucose fluctuations, and increased GV is associated with adverse cardiovascular outcomes. We systematically evaluated t

5 January 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
RAReza Amani‐Beni
Reza Amani‐Beni
BDBahar Darouei
Bahar Darouei
MMMohammadreza Mortaheb
Mohammadreza Mortaheb
MHMohammad Ali Haghighatpanah
Mohammad Ali Haghighatpanah
AWAlexei Wong
Alexei Wong
SMSadegh Mazaheri-Tehrani
Sadegh Mazaheri-Tehrani

4 June 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
AMArman Soltani Moghadam
Arman Soltani Moghadam
NKNasim Kakavand
Nasim Kakavand
FSFatemeh Ojaghi Shirmard
Fatemeh Ojaghi Shirmard
APAmirhossein Poopak
Amirhossein Poopak
NANazanin Anaraki
Nazanin Anaraki
KHKaveh Hosseini
Kaveh Hosseini

4 April 2025 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
RAReza Amani-Beni
Reza Amani-Beni
BDBahar Darouei
Bahar Darouei
SNSara Ghadimi Nooran
Sara Ghadimi Nooran
ASAtiyeh Karimi Shervedani
Atiyeh Karimi Shervedani
NKNasim Kakavand
Nasim Kakavand
MHMaryam Heidarpour
Maryam Heidarpour
Purpose This systematic review and meta-analysis aimed to evaluate the association between anti-Müllerian hormone (AMH) as a biomarker of ovarian reserve and various thyroid function tests, including thyroid-stimulating hormone (TSH), free T3 (FT3), free T4 (FT4), T3, T4, and thyroid autoantibodies, such as thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb), in various female populations. Methods A comprehensive literature search was conducted across six electronic databases and original observational studies examining the correlation between AMH levels and at least one TFT, TPOAb, or TgAb. Results Forty studies with 14,009 participants were included in the quantitative synthesis. The pooled results showed that AMH levels were not significantly correlated with TSH levels in the overall population or diverse subgroups. However, after adjusting for publication bias, a small, but significant, positive correlation was observed. Meta-regression analyses identified estradiol, FT3, and follicle-stimulating hormone (FSH) as significant moderators of AMH-TSH association in various populations. AMH was significantly positively correlated with FT3 (r = 0.177) and FT4 (r = 058), negatively correlated with T3 (r = − 0.202) and T4 (r = − 0.216) in the overall population, and significantly positively correlated with TPOAb in the normal population (r = 0.348). AMH levels were not significantly correlated with TgAb levels. Meta-regression revealed body mass index and FT4 as moderators in AMH-FT4 and AMH-TPOAb correlations. Conclusion These findings highlight the complex relationship between AMH and thyroid function markers with potential moderators influencing these associations. Further well-controlled longitudinal studies are required to clarify the underlying mechanisms and clinical implications of these associations across reproductive stages and metabolic profiles.

5 December 2025 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
RAReza Amani-Beni
Reza Amani-Beni
BDBahar Darouei
Bahar Darouei
NKNasim Kakavand
Nasim Kakavand
REReza Eshraghi
Reza Eshraghi
ASArsham Seifnezhad
Arsham Seifnezhad
AOAthar Omid
Athar Omid
Background: Eye-tracking technology provides an objective method for analyzing visual behavior during diagnostic tasks such as electrocardiogram (ECG) interpretation. As a high-stakes and visually complex clinical skill, ECG interpretation benefits from technologies that differentiate experts from novices via gaze patterns. We systematically reviewed eye-tracking in ECG research to examine links between gaze metrics and diagnostic performance and to appraise educational applications. Methods: Following PRISMA (PROSPERO CRD420251052940), we searched PubMed, Embase, Web of Science, Scopus, ERIC, IEEE Xplore, and PubPsych databases to September 2025. Eligible studies used eye-tracking during ECG interpretation and reported visual behavior or diagnostic outcomes. Two independent reviewers performed the study selection, data extraction, and quality assessment using the Jadad and Newcastle–Ottawa scales. Given heterogeneity, we conducted a narrative synthesis. Results: Nineteen studies (573 participants) were included, mainly involving students or early-career clinicians. Common metrics included fixation duration, counts, time to first fixation, and scan-path efficiency. Experts showed faster, more targeted fixation on critical leads (V1, V2, and II), shorter interpretation times, and higher accuracy. Novices exhibited scattered visual behavior and delayed attention to diagnostically relevant regions. Eye movement data were informative of underlying cognitive processes, including the selection, organization, and integration of ECG features. Additional factors, such as presentation format, individual experience, metacognitive strategies, and emotional responses, may moderate gaze behavior, although these were underexplored. Educational interventions leveraging expert gaze modeling or structured checklists showed mixed but promising outcomes. Conclusions: Eye-tracking differentiates expertise in ECG interpretation and may inform diagnostic reasoning, but prospective validation is needed. Gaze metrics are candidate indicators of performance and a foundation for feedback-based educational tools. Standardized protocols, larger multi-site studies, and inclusion of diverse learners are required to realize the potential of eye-tracking in ECG training and assessment. Graphical

30 September 2025 in Journal of Health, Population and Nutrition
Verified
Journal Article
Open access
PDF file
FSFatemeh Sabeti
Fatemeh Sabeti
DSDavood Shafie
Davood Shafie
NKNasim Kakavand
Nasim Kakavand
MFMohammad Fakhrolmobasheri
Mohammad Fakhrolmobasheri
AAAmirparsa Abhari
Amirparsa Abhari
NSNizal Sarrafzadegan
Nizal Sarrafzadegan
Metabolic syndrome (MetS) criteria include central obesity assessed by waist circumference (WC), which may be confounded by body weight. We evaluated whether substituting the weight-adjusted waist index (WWI) for WC improves prediction of long-term cardiovascular disease (CVD) events and mortality. To compare the prognostic performance of a WWI-based MetS definition versus the classic WC-based MetS definition for predicting CVD events and mortality, utilizing 17 years of follow-up data from the Isfahan Cohort Study (ICS). Of the 6,504 participants aged ≥ 35 years without prior CVD at baseline, 919 (14.1%) were lost to follow-up over 17 years. The remaining 5,585 participants were included in the final analysis. The classic and modified MetS definitions were compared using Cox regression analysis, Kaplan-Meier survival analysis, receiver operating characteristic (ROC) analysis, and risk reclassification by net reclassification improvement (NRI) for CVD events, CVD mortality, and all-cause mortality. The modified WWI-based MetS reclassified approximately 9.2% of participants and significantly improved risk classification for incident CVD events (NRI = + 0.41, p < 0.0001). In crude analyses, the modified MetS was associated with higher risk of incident CVD events compared to the classic definition. After full adjustment, associations attenuated but remained significant for CVD events (modified HR 1.19, 95% CI: 1.01–1.41; classic HR 1.25, 95% CI: 1.06–1.47), whereas associations with CVD and all-cause mortality lost significance. Kaplan–Meier analyses confirmed significant differences in survival by MetS status for both definitions. The modified definition demonstrated modest improvements in sensitivity, specificity, accuracy, and area under the ROC curve (AUC) (CVD events: 0.62 vs. 0.60; CVD mortality: 0.63 vs. 0.59; all-cause mortality: 0.59 vs. 0.55) for all outcomes compared to the classic definition. In this 17-year cohort, replacing WC with WWI in the MetS definition modestly improved prediction of cardiovascular events and mortality. Using WWI in MetS criteria may enhance risk stratification in clinical practice. Further studies are needed to validate these findings across diverse populations.